{"id":"ifn-beta-24-weeks","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Flu-like symptoms (fever, chills, myalgia)"},{"rate":"20-40","effect":"Injection site reactions"},{"rate":"20-30","effect":"Headache"},{"rate":"20-30","effect":"Fatigue"},{"rate":"10-20","effect":"Depression/mood changes"},{"rate":"10-15","effect":"Elevated liver enzymes"},{"rate":"5-10","effect":"Leukopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IFN beta is a type I interferon that binds to the interferon-alpha/beta receptor (IFNAR) on the cell surface, triggering JAK-STAT signaling pathways. This leads to upregulation of interferon-stimulated genes, enhanced natural killer cell activity, increased antigen presentation, and modulation of pro-inflammatory cytokine production. The net effect is enhanced innate immunity and potential anti-inflammatory effects depending on the disease context.","oneSentence":"Interferon beta activates innate immune responses by binding to interferon-beta receptors on immune cells, enhancing antiviral and immunomodulatory activity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:32.161Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple sclerosis (relapsing-remitting or secondary progressive forms)"}]},"trialDetails":[{"nctId":"NCT01753570","phase":"PHASE3","title":"Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-12","conditions":"Chronic Hepatitis C(CHC)","enrollment":74},{"nctId":"NCT01412333","phase":"PHASE3","title":"A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09-20","conditions":"Relapsing Multiple Sclerosis","enrollment":835},{"nctId":"NCT01247324","phase":"PHASE3","title":"A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-08-31","conditions":"Relapsing Multiple Sclerosis","enrollment":821},{"nctId":"NCT03387046","phase":"PHASE2","title":"A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2018-03-26","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":7},{"nctId":"NCT01514370","phase":"PHASE2","title":"Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2012-04-30","conditions":"Multiple Sclerosis","enrollment":80},{"nctId":"NCT01085318","phase":"PHASE4","title":"Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2010-06-30","conditions":"Multiple Sclerosis","enrollment":38},{"nctId":"NCT01156311","phase":"PHASE2","title":"BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis","status":"COMPLETED","sponsor":"Biogen","startDate":"2010-06","conditions":"Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis","enrollment":108},{"nctId":"NCT01939002","phase":"PHASE3","title":"Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)","status":"COMPLETED","sponsor":"Biogen","startDate":"2013-11","conditions":"Relapsing Multiple Sclerosis","enrollment":251},{"nctId":"NCT02117050","phase":"PHASE4","title":"RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate","status":"TERMINATED","sponsor":"EMD Serono","startDate":"2014-06","conditions":"Multiple Sclerosis","enrollment":1},{"nctId":"NCT01808885","phase":"PHASE1","title":"Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-04","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":44},{"nctId":"NCT00370071","phase":"PHASE3","title":"Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-11","conditions":"Multiple Sclerosis","enrollment":39},{"nctId":"NCT00404352","phase":"PHASE3","title":"REbif FLEXible Dosing in Early Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2006-11","conditions":"Multiple Sclerosis","enrollment":517},{"nctId":"NCT00249860","phase":"PHASE3","title":"A Multicenter Phase 3 Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2002-09","conditions":"Hepatitis C","enrollment":257},{"nctId":"NCT00811395","phase":"PHASE2","title":"Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-10","conditions":"Multiple Sclerosis","enrollment":182},{"nctId":"NCT00489489","phase":"PHASE2","title":"Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-05","conditions":"Multiple Sclerosis","enrollment":118},{"nctId":"NCT00185250","phase":"PHASE2","title":"Betaferon/ Betaseron (Interferon Beta-1b) in Patients With Chronic Viral Cardiomyopathy","status":"COMPLETED","sponsor":"Bayer","startDate":"2002-12","conditions":"Cardiomyopathies, Heart Diseases","enrollment":138}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"IFN beta(24 weeks)","genericName":"IFN beta(24 weeks)","companyName":"Tanabe Pharma Corporation","companyId":"tanabe-pharma-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IFN beta is used to treat conditions such as Relapsing Multiple Sclerosis, Multiple Sclerosis, and Relapsing Remitting Multiple Sclerosis. The mechanism of IFN beta is not specified in the provided facts, but it is listed as an intervention in various studies on ClinicalTrials.gov.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}